Drug Profile
Research programme: pluripotent stem cell therapy - Cynata Therapeutics
Alternative Names: Cymerus™ mesenchymal stem cells; Cymerus™ MSCLatest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator Cynata Therapeutics
- Developer Cynata Therapeutics; Monash University; Royal College of Surgeons
- Class Antineoplastics; Immunotherapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Immunological disorders
Highest Development Phases
- Preclinical Idiopathic pulmonary fibrosis; Renal transplant rejection
- No development reported Asthma; Cancer; Diabetic foot ulcer; Immunological disorders; Myocardial infarction; Sepsis
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for preclinical development in Asthma in Australia (Intranasal, Infusion)
- 28 Dec 2022 No recent reports of development identified for preclinical development in Asthma in Australia (IV, Infusion)
- 28 Dec 2022 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)